Blog
RSS FeedPosted by Michael Wonder on 25 Mar 2019
Melbourne's Peter MacCallum Cancer Centre to be home of 'the next great wave in treatment'
25 March 2019 - A new form of cancer treatment that uses cell therapy to attack the disease will become ...
Posted by Michael Wonder on 18 Mar 2019
Chile takes several ‘unorthodox’ steps to push back on drug prices, angering pharma
18 March 2019 - Searching for ways to beat back rising drug costs, the Chilean legislature is advancing three measures ...
Posted by Michael Wonder on 18 Mar 2019
Ohio accuses UnitedHealth's OptumRx of drug overcharges in lawsuit
18 March 2019 - Ohio’s attorney general on Monday said he had filed a lawsuit against UnitedHealth Group Inc’s OptumRx unit, ...
Posted by Michael Wonder on 18 Mar 2019
Medicines only work if patients can afford them: solutions for the high drug prices era
18 March 2019 - Since 2000, more than 500 new medicines have been approved by the FDA. ...
Posted by Michael Wonder on 18 Mar 2019
U.S. FDA accepts BLA filing of Aimmune Therapeutics’ AR101 for peanut allergy
18 March 2019 - If approved, AR101 will be the first medicine for this life-threatening condition. ...
Posted by Michael Wonder on 18 Mar 2019
Allergan announces FDA approval of Avycaz (ceftazidime and avibactam) for paediatric patients
18 March 2019 - Label now includes new data on use of Avycaz for treatment of cUTI and cIAI in paediatric ...
Posted by Michael Wonder on 18 Mar 2019
The policy initiatives Scott Gottlieb championed at the FDA will remain after he departs
18 March 2019 - The resignation of Scott Gottlieb as commissioner of the Food and Drug Administration raises a big ...
Posted by Michael Wonder on 18 Mar 2019
The impact of pharmaceutical rebates on patients’ drug expenditures
18 March 2019 - The drug-pricing landscape in Canada is complex, with 4 different agencies and each provincial, territorial and federal ...
Posted by Michael Wonder on 18 Mar 2019
Three new drugs added to PBS to ease cost pain
19 March 2019 - Three new treatments to help save or prolong the lives of thousands of Australians suffering from ...
Posted by Michael Wonder on 18 Mar 2019
New early breast cancer drug to reduce risk of recurrence or death approved for Australian women
18 March 2019 - Nerlynx (neratinib) now approved by the Therapeutic Goods Administration for Australian women. ...
Posted by Michael Wonder on 18 Mar 2019
CytoDyn reaches historical milestone, submits first of three sections of BLA to FDA for leronlimab (PRO 140) as a combination therapy for HIV
18 March 2019 - FDA previously granted rolling review for BLA. ...
Posted by Michael Wonder on 18 Mar 2019
Outside political groups not always what they appear
18 March 2019 - As ominous music plays in the background, the narrator of a radio ad echoes objections from ...
Posted by Michael Wonder on 18 Mar 2019
CMA drops anti-competitive case against MSD
18 March 2019 - The Competition and Markets Authority has closed its investigation into a suspected anti-competitive discount scheme developed ...
Posted by Michael Wonder on 18 Mar 2019
NICE celebrates its 20th anniversary
18 March 2019 - Organisation was founded in April 1999 to improve outcome for health service users ...
Posted by Michael Wonder on 18 Mar 2019
Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
15 March 2019 - Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome ...
Posted by Michael Wonder on 18 Mar 2019
Brexit - implications for therapeutic goods in Australia
18 March 2019 - In the event of a 'no deal' exit of the United Kingdom from the European Union, ...